Craft

Xintela

Revenue

KR78 K

FY, 2023

Xintela Summary

Company Summary

Overview
Xintela is a biomedical company working in the fields of regenerative medicine and cancer. Its marker technology XINMARK is used to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis, as well as for the development of an antibody-based treatment against specific tumors.
Type
Public
Status
Active
Founded
2009
HQ
Lund, SE | view all locations
Website
http://xintela.se/en/home
Cybersecurity rating
Sectors

Key People

  • Evy Lundgren-Åkerlund

    Evy Lundgren-Åkerlund, Chief Executive Officer

  • Gregory Batcheller

    Gregory Batcheller, Chairman of the Board

  • Lars Hedbys
  • Gunnar Telhammar

LocationsView all

3 locations detected

  • Lund, Skåne län HQ

    Sweden

    Scheelevägen 8

  • Lund, Skåne County

    Sweden

  • Lund, Skåne län

    Sweden

    Scheeletorget 1

Xintela Financials

Summary Financials

Revenue (Q1, 2024)
kr299.0K
Gross profit (Q1, 2024)
kr310.0K
Net income (Q1, 2024)
(kr11.0M)
Cash (Q1, 2024)
kr10.4M
EBIT (Q1, 2024)
(kr10.8M)

Footer menu